A randomized phase I study comparing the pharmacokinetics of a bevacizumab (HD204) biosimilar to European Union- and United States of America-sourced bevacizumab

por Demarchi, Martin, Coliat, Pierre, Barthelemy, Philippe, Schott, Roland, BenAbdelghani, Meher, Kim, Michael, Hii, Jocelyn Chung Shii, Feyaerts, Peggy, Ang, Felicia Rui Xia, Derde, Marie Paule, Deforce, Filip, Petit, Thierry, Schwabe, Chris, Wynne, Chris, Park, Lisa Soyeon, Pivot, Xavier
Publicado 2021